Induction of revertant fibres in the mdx mouse using antisense oligonucleotides

[1]  P. Iversen,et al.  Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD , 2006, Gene Therapy.

[2]  S. Wilton,et al.  Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide , 2006, The journal of gene medicine.

[3]  Ramil N. Nurtdinov,et al.  Alternative splicing and protein function , 2005, BMC Bioinformatics.

[4]  M. Byrom,et al.  Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis , 2005, Nucleic acids research.

[5]  J. Morgan,et al.  Duchenne's muscular dystrophy: animal models used to investigate pathogenesis and develop therapeutic strategies , 2003, International journal of experimental pathology.

[6]  C. Mann,et al.  Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse , 2003, Nature Medicine.

[7]  Jinhua Wang,et al.  ESEfinder: a web resource to identify exonic splicing enhancers , 2003, Nucleic Acids Res..

[8]  C. Mann,et al.  Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene , 2003, The journal of gene medicine.

[9]  C. Mann,et al.  Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy , 2002, The journal of gene medicine.

[10]  N. Bresolin,et al.  The dystrophin gene is alternatively spliced throughout its coding sequence , 2002, FEBS letters.

[11]  F. Baas,et al.  Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. , 2001, Human molecular genetics.

[12]  P. Iversen.  Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation. , 2001, Current opinion in molecular therapeutics.

[13]  C. Mann,et al.  Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[14]  S. Wilton,et al.  Massive Idiosyncratic Exon Skipping Corrects the Nonsense Mutation in Dystrophic Mouse Muscle and Produces Functional Revertant Fibers by Clonal Expansion , 2000, The Journal of cell biology.

[15]  J. Summerton.  Morpholino antisense oligomers: the case for an RNase H-independent structural type. , 1999, Biochimica et biophysica acta.

[16]  S. Agrawal,et al.  Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides , 1999, Neuromuscular Disorders.

[17]  A. Sadeghi,et al.  Redefinition of dystrophin isoform distribution in mouse tissue by RT-PCR implies role in nonmuscle manifestations of duchenne muscular dystrophy. , 1998, Molecular genetics and metabolism.

[18]  C. Mann,et al.  Alternative dystrophin gene transcripts in golden retriever muscular dystrophy , 1998, Muscle & nerve.

[19]  C. Milcarek,et al.  Expression of the thyroid hormone receptor gene, erbAalpha, in B lymphocytes: alternative mRNA processing is independent of differentiation but correlates with antisense RNA levels. , 1997, Nucleic acids research.

[20]  N. Laing,et al.  Revertant fibres: a possible genetic therapy for Duchenne muscular dystrophy? , 1997, Neuromuscular Disorders.

[21]  N. Laing,et al.  Dystrophin gene transcripts skipping the mdx mutation , 1997, Muscle & nerve.

[22]  S. Wilton,et al.  Bandstab: a PCR-based alternative to cloning PCR products. , 1997, BioTechniques.

[23]  G. Danieli,et al.  Duchenne phenotype with in‐frame deletion removing major portion of dystrophin rod: Threshold effect for deletion size? , 1996, Muscle & nerve.

[24]  G. Danieli,et al.  Dystrophin‐positive fibers in duchenne dystrophy: Origin and correlation to clinical course , 1995, Muscle & nerve.

[25]  T. Helliwell,et al.  Characterization of revertant muscle fibers in Duchenne muscular dystrophy, using exon-specific monoclonal antibodies against dystrophin. , 1995, American journal of human genetics.

[26]  T. Miike,et al.  PCR and immunocytochemical analyses of dystrophin-positive fibers in Duchenne muscular dystrophy , 1995, Journal of the Neurological Sciences.

[27]  K. Bushby,et al.  Becker muscular dystrophy with onset after 60 years , 1994, Neurology.

[28]  Y. Takeshima,et al.  Amino‐terminal deletion of 53% of dystrophin results in an intermediate Duchenne‐Becker muscular dystrophy phenotype , 1994, Neurology.

[29]  M. Passos-Bueno,et al.  Half the dystrophin gene is apparently enough for a mild clinical course: confirmation of its potential use for gene therapy. , 1994, Human molecular genetics.

[30]  M. Noble,et al.  Myogenic cell lines derived from transgenic mice carrying a thermolabile T antigen: a model system for the derivation of tissue-specific and mutation-specific cell lines. , 1994, Developmental biology.

[31]  K. Davies,et al.  Dystrophin and dystrophin-related proteins: A review of protein and RNA studies , 1993, Neuromuscular Disorders.

[32]  F. Muntoni,et al.  Muscular weakness in the mdx mouse , 1993, Journal of the Neurological Sciences.

[33]  T. Vulliamy,et al.  Exon skipping and translation in patients with frameshift deletions in the dystrophin gene. , 1993, American journal of human genetics.

[34]  K. Bushby,et al.  Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 3. Differential diagnosis and prognosis. , 1993, Journal of medical genetics.

[35]  L. Kunkel,et al.  The structural and functional diversity of dystrophin , 1993, Nature Genetics.

[36]  D. Libri,et al.  Pre‐mRNA secondary structure and the regulation of splicing , 1993, BioEssays : news and reviews in molecular, cellular and developmental biology.

[37]  V. Chapman,et al.  The Frequency of Revertants in mdx Mouse Genetic Models for Duchenne Muscular Dystrophy , 1992, Pediatric Research.

[38]  R. Bartlett,et al.  An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. , 1992, Genomics.

[39]  J. Mendell,et al.  Somatic reversion/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers. , 1992, American journal of human genetics.

[40]  R Kole,et al.  Selection of splice sites in pre-mRNAs with short internal exons , 1991, Molecular and cellular biology.

[41]  H Sugita,et al.  Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. , 1991, American journal of human genetics.

[42]  J. Mendell,et al.  Dystrophin expression and somatic reversion in prednisone‐treated and untreated Duchenne dystrophy , 1991, Neurology.

[43]  Simon C Watkins,et al.  Somatic reversion/suppression of the mouse mdx phenotype in vivo , 1990, Journal of the Neurological Sciences.

[44]  K. Davies,et al.  Very mild muscular dystrophy associated with the deletion of 46% of dystrophin , 1990, Nature.

[45]  Marvin B. Shapiro,et al.  RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. , 1987, Nucleic acids research.

[46]  K. Moore,et al.  X chromosome-linked muscular dystrophy (mdx) in the mouse. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[47]  G. van Ommen,et al.  Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. , 2004, American journal of human genetics.

[48]  G. van Ommen,et al.  Advances in Duchenne muscular dystrophy gene therapy , 2003, Nature reviews. Genetics.

[49]  A. J. Lopez,et al.  Alternative splicing of pre-mRNA: developmental consequences and mechanisms of regulation. , 1998, Annual review of genetics.

[50]  W. King,et al.  Characterization of translational frame exception patients in Duchenne/Becker muscular dystrophy. , 1993, Human molecular genetics.

[51]  A. Monaco,et al.  An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. , 1988, Genomics.

[52]  Eric P. Hoffman,et al.  Dystrophin: The protein product of the duchenne muscular dystrophy locus , 1987, Cell.